Close the commercialization and license agreement for BAT1806
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 22 Apr 2021
- Due
- 30 Jun 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The transaction is expected to close in the second quarter of 2021.”
What we found
Evidence strength A What the grades mean
The 8-K shows a $30 million upfront payment under the Bio-Thera BAT1806 agreement recorded in Q2 2021, implying closing by June 30, 2021, though no exact closing date is given.
-
A Biogen 8-K filed 2021-07-22
“Second quarter 2021 GAAP and Non-GAAP R&D expense includes a $30 million upfront payment related to a commercialization and license agreement with Bio-Thera Solutions, Ltd. (Bio-Thera)” ✓ confirmed on the page
-
A Biogen 10-K filed 2022-02-03
“In June 2021 we and Bio-Thera Solutions, Ltd. (Bio-Thera) announced positive results that the Phase 3 study of BAT1806” ✓ confirmed on the page
Market reaction: the shares moved +1.3% against the S&P 500 over the three sessions around the disclosure (21 Jul 2021 to 26 Jul 2021). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Transaction other
- Indicative materiality
- Medium rules
- Action
- Close
- Deliverable
- BAT1806 commercialization and license agreement
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: contingent upon completion of review under antitrust laws
- Depends on
- Regulatory, Counterparty
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Biogen? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-BIIB-005340 · Corrections policy